Jaguar Health Swaps $3.4M of Debt for 481,584 Shares with Streeterville
JAGX has more than doubled off its 52-week low of $2.35 on elevated volume (26× avg).
Summary
Jaguar Health exchanged $3.4 million of its 2021 Note for 481,584 newly issued shares, cutting secured debt but adding immediate resale overhang to a thinly traded stock.
Key Events · Financing and Capital Events · JAGX
-
Debt-for-Equity Exchange with Streeterville
Issued 481,584 shares to Streeterville Capital in exchange for a $3,400,000 reduction in the outstanding balance of the 2021 Note.
-
Immediate Resale Overhang
Exchange shares were issued under Section 3(a)(9) with no restrictive legend, allowing Streeterville to sell them immediately into the market.
-
Post-Exchange Share Count
Company reports approximately 1,945,542 shares outstanding after the exchange, up from roughly 1.46 million shares prior to the issuance.
-
Balance Sheet Relief
The $3.4 million debt reduction is significant relative to the company's $3.8 million cash balance and going concern warning disclosed in the Q2 2026 10-Q.
Analysis · JAGX · Life Sciences
A $3.4 million reduction in the outstanding 2021 Note balance was achieved by issuing 481,584 shares to Streeterville Capital. This eliminates a meaningful portion of secured debt for a company with only $3.8 million in cash and a going concern warning, but it also adds roughly 25% to the post-split share count of 1.95 million shares. Because the shares were issued without restrictive legends under Section 3(a)(9), Streeterville can sell them immediately, creating near-term selling pressure on a stock already trading at $7.08 after a 1-for-15 reverse split.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $7.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $2.35 to $1,280.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.